# A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies

> **NCT05269940** · PHASE1,PHASE2 · COMPLETED · sponsor: **Nanjing Zenshine Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Non Hodgkin Lymphoma
- Peripheral T Cell Lymphoma
- CLL/SLL

## Interventions

- **DRUG:** ZX-101A

## Key facts

- **NCT ID:** NCT05269940
- **Lead sponsor:** Nanjing Zenshine Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-17
- **Primary completion:** 2023-01-24
- **Final completion:** 2024-07-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05269940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05269940, "A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05269940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*